InterCure achieved annual revenue of NIS 356 million and adjusted EBITDA of NIS 61 million, representing 17% of revenues.
The company maintained profitability for the fourteenth and fifteenth consecutive quarters despite challenges.
InterCure continues to expand its product portfolio and dedicated medical cannabis pharmacy chain.
The company is entitled to full compensation for damages caused by the terrorist attack and war in Gaza, receiving tens of millions of NIS as advance payments.
InterCure plans to launch its first products in Germany and expects sequential quarterly growth in 2024.